Chromomycose cutanée diffuse à Phialophora verrucosa

Radouane, N.; Hali, F.; Khadir, K.; Soussi, M; Ouakadi, A.; Marouane, S.; Zamiati, S.; Benchikhi, H.

doi:10.1016/j.annder.2012.10.605

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phialophora spp. was also found in some African countries at a high frequency, such as Libya, Madagascar, Kenya, South Africa, Morocco, and Djibouti [ 95 , 104 , 119 , 130 , 132 , 150 , 153 , 160 ].…”

Section: Resultsmentioning

confidence: 92%

“…A total of 65 articles were selected between 1947 and 2018 describing 1,875 patients distributed between Madagascar (1,323 cases) [ 94 – 99 ], South Africa (156 cases) [ 100 – 106 ], Republic of the Congo and Democratic Republic of the Congo (121 cases) [ 107 – 115 ], Gabon (64 cases) [ 116 ], Zimbabwe (35 cases) [ 117 ], Uganda (34 cases) [ 118 ], Kenya (33 cases) [ 119 ], Cameroon (23 cases) [ 120 – 123 ], Morocco (18 cases) [ 124 – 132 ], Tanzania (17 cases) [ 133 , 134 ], Ethiopia (14 cases) [ 135 , 136 ], Angola (7 cases) [ 115 , 137 , 138 ], Nigeria (5 cases) [ 138 – 141 ], Tunisia (5 cases) [ 142 – 146 ], Reunion Island (5 cases) [ 147 – 149 ], Libya (4 cases) [ 150 – 153 ], Comoro Island (4 cases) [ 154 , 155 ], Sierra Leone (3 cases) [ 156 ], Senegal (2 cases) [ 157 , 158 ], Botswana (1 case) [ 159 ] and Djibouti (1 case) [ 160 ]. There are descriptions of CBM in Chad and the Ivory Coast.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The global burden of chromoblastomycosis

et al. 2021

View full text Add to dashboard Cite

Background Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination. Methods and findings In order to estimate the global burden of CBM, we retrospectively reviewed the published literature from 1914 to 2020. Over the 106-year period, a total of 7,740 patients with CBM were identified on all continents except Antarctica. Most of the cases were reported from South America (2,619 cases), followed by Africa (1,875 cases), Central America and Mexico (1,628 cases), Asia (1,390 cases), Oceania (168 cases), Europe (35 cases), and USA and Canada (25 cases). We described 4,022 (81.7%) male and 896 (18.3%) female patients, with the median age of 52.5 years. The average time between the onset of the first lesion and CBM diagnosis was 9.2 years (range between 1 month to 50 years). The main sites involved were the lower limbs (56.7%), followed by the upper limbs (19.9%), head and neck (2.9%), and trunk (2.4%). Itching and pain were reported by 21.5% and 11%, respectively. Malignant transformation was described in 22 cases. A total of 3,817 fungal isolates were cultured, being 3,089 (80.9%) Fonsecaea spp., 552 (14.5%) Cladophialophora spp., and 56 Phialophora spp. (1.5%). Conclusions and significance This review represents our current knowledge on the burden of CBM world-wide. The global incidence remains unclear and local epidemiological studies are required to improve these data, especially in Africa, Asia, and Latin America. The recognition of CBM as NTD emphasizes the need for public health efforts to promote support for all local governments interested in developing specific policies and actions for preventing, diagnosing and assisting patients.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

The global burden of chromoblastomycosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Phialophora verrucosa is a dematiaceous fungus associated with several diseases including chromoblastomycosis (CBM), phaeohyphomycosis and mycetoma [1][2][3] . However, the main mycosis caused by this fungus is CBM 4 . Although no gold standard therapy for CBM has been proposed, itraconazole is the most commonly used antifungal agent.…”

Section: Introductionmentioning

confidence: 99%

Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

Granato

Sousa

Rosa

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

“…Although diabetic patients have an increased risk of mycotic infections such as mucormycosis, current evidence shows only 2 documented cases of CBM in these patients. 17,18 The fact that CBM was diagnosed by a dermatopathologist in our reported patient demonstrates the importance of close communication between dermatologists and pathologists to make an early diagnosis and to provide the patient with early appropriate therapy, both of which are fundamental to improving patients' quality of life.…”

Section: Discussionmentioning

confidence: 89%

Chromoblastomycosis in a Diabetic Patient Without a History of Trauma

Zarei

Schneider

Villasante

et al. 2015

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Chromoblastomycosis (CBM) is a slowly progressive cutaneous and subcutaneous mycosis mostly seen in tropical and subtropical areas and Fonsecaea pedrosoi is the most common cause. The authors describe the case of a diabetic Haitian woman, presenting with a chronic verrucous plaque without any history of trauma. Her histopathologic results showed epidermal hyperplasia and sclerotic bodies, which are diagnostic for CBM. Her therapy began with itraconazole 200 mg tablets twice a day. The unique feature of this patient is the coincidence of diabetes and CBM. However, to the best of our knowledge, this is the first documented case of human CBM in Miami, FL, which develops the awareness regarding this diagnosis among doctors in this area. There should be a close communication between dermatologists and pathologists to make an early diagnosis of CBM and also adequate therapy, which both are fundamental to improve patient's quality of life.

show abstract

Chromomycose cutanée diffuse à Phialophora verrucosa

Cited by 6 publications

References 13 publications

The global burden of chromoblastomycosis

The global burden of chromoblastomycosis

Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

Chromoblastomycosis in a Diabetic Patient Without a History of Trauma

Contact Info

Product

Resources

About